, Columnist
Pharma Gets Roped Into the Trumpcare Maelstrom
Proposed changes to the Obamacare replacement plan could crush drug sales.
This article is for subscribers only.
When you rush any kind of massive project, you raise the risk that people get hurt.
That's certainly the case with health-care reform. As President Donald Trump and congressional Republicans scramble to save their troubled attempt to repeal and replace the Affordable Care Act, they are considering last-second changes -- including one that could add Big Pharma to the list of those damaged by the bill. This would further immiserate an industry already dogged by the president's repeated drug-pricing broadsides.